Thr735
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr735  -  Abl (human)

Site Information
DTEWRSVtLPRDLQS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450291

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 7 ) , immunoprecipitation ( 7 ) , mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 7 , 8 ) , phospho-antibody ( 4 , 6 , 7 , 8 ) , western blotting ( 4 , 6 )
Disease tissue studied:
breast cancer ( 7 ) , colorectal cancer ( 7 ) , colorectal carcinoma ( 7 ) , gastric cancer ( 3 ) , gastric carcinoma ( 3 ) , leukemia ( 4 ) , chronic myelogenous leukemia ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
CLK1 (human) ( 6 ) , CLK4 (human) ( 6 ) , MST1 (human) ( 6 ) , MST2 (human) ( 6 ) , TTK (human) ( 6 )
Putative in vivo kinases:
TTK (human) ( 6 )
Kinases, in vitro:
CLK1 (human) ( 6 ) , CLK4 (human) ( 6 ) , Cot (human) ( 5 ) , MST1 (human) ( 6 ) , MST2 (human) ( 6 ) , TTK (human) ( 6 )
Treatments:
adriamycin ( 6 , 8 ) , H2O2 ( 6 ) , imatinib ( 4 ) , RAD001 ( 4 ) , siRNA ( 6 )

Downstream Regulation
Effects of modification on Abl:
enzymatic activity, induced ( 6 ) , intracellular localization ( 4 , 6 , 7 ) , molecular association, regulation ( 7 , 8 )
Effects of modification on biological processes:
apoptosis, induced ( 4 , 7 ) , apoptosis, inhibited ( 6 , 8 )
Induce interaction with:
14-3-3 beta (human) ( 8 )
Inhibit interaction with:
14-3-3 beta (human) ( 7 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

3

Moritz A (2010) CST Curation Set: 9979; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

4

Mancini M, et al. (2010) mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein. Leuk Res 34, 641-8
19643477   Curated Info

5

Wu B, Jiang P, Mu Y, Wilmouth RC (2009) Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210. Biol Chem 390, 1271-7
19804365   Curated Info

6

Nihira K, Taira N, Miki Y, Yoshida K (2008) TTK/Mps1 controls nuclear targeting of c-Abl by 14-3-3-coupled phosphorylation in response to oxidative stress. Oncogene 27, 7285-95
18794806   Curated Info

7

Raina D, et al. (2006) MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 25, 3774-83
16888623   Curated Info

8

Yoshida K, et al. (2005) JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 7, 278-85
15696159   Curated Info